Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy f...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2024
|
| In: |
Leukemia
Year: 2024, Jahrgang: 38, Heft: 8, Pages: 1722-1730 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/s41375-024-02341-4 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41375-024-02341-4 Verlag, lizenzpflichtig, Volltext: http://www.nature.com/articles/s41375-024-02341-4 
|
| Verfasserangaben: | Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E. Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J.W.M. Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G. Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann and Susanne Saussele |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1917405006 | ||
| 003 | DE-627 | ||
| 005 | 20250716232304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-024-02341-4 |2 doi | |
| 035 | |a (DE-627)1917405006 | ||
| 035 | |a (DE-599)KXP1917405006 | ||
| 035 | |a (OCoLC)1528019123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Efficace, Fabio |e VerfasserIn |0 (DE-588)1097426165 |0 (DE-627)857230166 |0 (DE-576)468709231 |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors |b results from the EURO-SKI Trial |c Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E. Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J.W.M. Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G. Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann and Susanne Saussele |
| 264 | 1 | |c August 2024 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 10. Juli 2024 | ||
| 500 | |a Gesehen am 17.02.2025 | ||
| 520 | |a Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients. | ||
| 650 | 4 | |a Leukaemia | |
| 650 | 4 | |a Signs and symptoms | |
| 700 | 1 | |a Mahon, Francois-Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richter, Johan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Piciocchi, Alfonso |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cipriani, Marta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nicolini, Franck E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayer, Jiri |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zackova, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janssen, Jeroen J. W. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Panayiotidis, Panayiotis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vestergaard, Hanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koskenvesa, Perttu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Almeida, Antonio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hjorth-Hansen, Henrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martinez-Lopez, Joaquin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Olsson-Strömberg, Ulla |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Hochhaus, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1107039339 |0 (DE-627)863321976 |0 (DE-576)474976130 |4 aut | |
| 700 | 1 | |a Berger, Marc G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Etienne, Gabriel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klamova, Hana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Faber, Edgar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rousselot, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfirrmann, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 38(2024), 8 vom: Aug., Seite 1722-1730 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors results from the EURO-SKI Trial |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:8 |g month:08 |g pages:1722-1730 |g extent:9 |a Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors results from the EURO-SKI Trial |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41375-024-02341-4 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.nature.com/articles/s41375-024-02341-4 |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20250217 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |d 60000 |e 60000PS115839860 |e 61200PS115839860 |e 60000PS115839860 |k 0/60000/ |k 1/60000/61200/ |k 0/60000/ |p 24 |y j | ||
| 999 | |a KXP-PPN1917405006 |e 466506699X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors","subtitle":"results from the EURO-SKI Trial","title":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors"}],"recId":"1917405006","name":{"displayForm":["Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E. Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J.W.M. Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G. Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann and Susanne Saussele"]},"origin":[{"dateIssuedDisp":"August 2024","dateIssuedKey":"2024"}],"person":[{"role":"aut","given":"Fabio","display":"Efficace, Fabio","family":"Efficace"},{"family":"Mahon","display":"Mahon, Francois-Xavier","given":"Francois-Xavier","role":"aut"},{"role":"aut","display":"Richter, Johan","given":"Johan","family":"Richter"},{"display":"Piciocchi, Alfonso","given":"Alfonso","family":"Piciocchi","role":"aut"},{"display":"Cipriani, Marta","given":"Marta","family":"Cipriani","role":"aut"},{"display":"Nicolini, Franck E.","given":"Franck E.","family":"Nicolini","role":"aut"},{"role":"aut","display":"Mayer, Jiri","given":"Jiri","family":"Mayer"},{"role":"aut","display":"Zackova, Daniela","given":"Daniela","family":"Zackova"},{"role":"aut","family":"Janssen","given":"Jeroen J. W. M.","display":"Janssen, Jeroen J. W. M."},{"role":"aut","family":"Panayiotidis","display":"Panayiotidis, Panayiotis","given":"Panayiotis"},{"display":"Vestergaard, Hanne","given":"Hanne","family":"Vestergaard","role":"aut"},{"role":"aut","given":"Perttu","display":"Koskenvesa, Perttu","family":"Koskenvesa"},{"role":"aut","family":"Almeida","display":"Almeida, Antonio","given":"Antonio"},{"family":"Hjorth-Hansen","given":"Henrik","display":"Hjorth-Hansen, Henrik","role":"aut"},{"family":"Martinez-Lopez","given":"Joaquin","display":"Martinez-Lopez, Joaquin","role":"aut"},{"role":"aut","given":"Ulla","display":"Olsson-Strömberg, Ulla","family":"Olsson-Strömberg"},{"family":"Hochhaus","display":"Hochhaus, Andreas","given":"Andreas","role":"aut"},{"role":"aut","given":"Marc G.","display":"Berger, Marc G.","family":"Berger"},{"given":"Gabriel","display":"Etienne, Gabriel","family":"Etienne","role":"aut"},{"role":"aut","display":"Klamova, Hana","given":"Hana","family":"Klamova"},{"role":"aut","family":"Faber","display":"Faber, Edgar","given":"Edgar"},{"given":"Philippe","display":"Rousselot, Philippe","family":"Rousselot","role":"aut"},{"role":"aut","family":"Pfirrmann","display":"Pfirrmann, Markus","given":"Markus"},{"given":"Susanne","display":"Saußele, Susanne","family":"Saußele","role":"aut"}],"relHost":[{"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia","title":"Leukemia"}],"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997"}],"note":["Gesehen am 15.03.04"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2008023-2"],"issn":["1476-5551"],"eki":["32046699X"]},"part":{"text":"38(2024), 8 vom: Aug., Seite 1722-1730","volume":"38","year":"2024","pages":"1722-1730","extent":"9","issue":"8"},"language":["eng"],"recId":"32046699X","disp":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors results from the EURO-SKI TrialLeukemia","pubHistory":["Nachgewiesen 11.1997 -"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Online veröffentlicht: 10. Juli 2024","Gesehen am 17.02.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1917405006"],"doi":["10.1038/s41375-024-02341-4"]},"physDesc":[{"extent":"9 S."}]} | ||
| SRT | |a EFFICACEFAHEALTHRELA2024 | ||